Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

Overview

Journal Diabetes

Specialty Endocrinology

Date 2022 Mar 22

PMID 35316839

Authors

Emily K Sims

Rachel E J Besser

Colin Dayan

Cristy Geno Rasmussen

Carla Greenbaum

Kurt J Griffin

William Hagopian

Mikael Knip

Anna E Long

Frank Martin

Chantal Mathieu

Marian Rewers

Andrea K Steck

John M Wentworth

Stephen S Rich

Olga Kordonouri

Anette-Gabriele Ziegler

Kevan C Herold

Affiliations

Soon will be listed here.

Abstract

Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. However, ∼90% of those who develop type 1 diabetes do not have a family history. Recent successes in disease-modifying therapies to impact the course of early-stage disease have ignited the consideration of the need for and feasibility of population screening to identify those at increased risk. Existing population screening programs rely on genetic or autoantibody screening, and these have yielded significant information about disease progression and approaches for timing for screening in clinical practice. At the March 2021 Type 1 Diabetes TrialNet Steering Committee meeting, a session was held in which ongoing efforts for screening in the general population were discussed. This report reviews the background of these efforts and the details of those programs. Additionally, we present hurdles that need to be addressed for successful implementation of population screening and provide initial recommendations for individuals with positive screens so that standardized guidelines for monitoring and follow-up can be established.

Citing Articles

IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.

Sims E, Cuthbertson D, Ferrat L, Bosi E, Evans-Molina C, DiMeglio L Diabetologia. 2025; .

PMID: 40016443 DOI: 10.1007/s00125-025-06382-x.

A type 1 diabetes prediction model has utility across multiple screening settings with recalibration.

Templeman E, Ferrat L, Parikh H, You L, Triolo T, Steck A Res Sq. 2025; .

PMID: 39975907 PMC: 11838734. DOI: 10.21203/rs.3.rs-5773430/v1.

Standardized Measurement of Type 1 Diabetes Polygenic Risk Across Multi-Ancestry Population Cohorts.

Luckett A, Oram R, Deutsch A, Ortega H, Fraser D, Ashok K medRxiv. 2025; .

PMID: 39867414 PMC: 11759247. DOI: 10.1101/2025.01.16.25320691.

Autoimmune Type 1 Diabetes: An Early Approach Appraisal for Spain by the AGORA Diabetes Collaborative Group.

Gomez-Peralta F, Pines-Corrales P, Santos E, Cuesta M, Gonzalez-Albarran O, Azriel S J Clin Med. 2025; 14(2).

PMID: 39860426 PMC: 11766439. DOI: 10.3390/jcm14020418.

Pre-Type 1 Diabetes in Adolescents and Teens: Screening, Nutritional Interventions, Beta-Cell Preservation, and Psychosocial Impacts.

Sundheim B, Hirani K, Blaschke M, Lemos J, Mittal R J Clin Med. 2025; 14(2).

PMID: 39860389 PMC: 11765808. DOI: 10.3390/jcm14020383.

References

Livingstone S, Levin D, Looker H, Lindsay R, Wild S, Joss N . Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015; 313(1):37-44. PMC: 4426486. DOI: 10.1001/jama.2014.16425. View

Verge C, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson R . Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996; 45(7):926-33. DOI: 10.2337/diab.45.7.926. View

Sosenko J, Skyler J, Herold K, Palmer J . The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes. 2012; 61(6):1331-7. PMC: 3357303. DOI: 10.2337/db11-1660. View

Hekkala A, Ilonen J, Toppari J, Knip M, Veijola R . Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatr Diabetes. 2017; 19(2):314-319. DOI: 10.1111/pedi.12541. View

Bottazzo G, Florin-Christensen A, Doniach D . Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974; 2(7892):1279-83. DOI: 10.1016/s0140-6736(74)90140-8. View

Chmiel R, Giannopoulou E, Winkler C, Achenbach P, Ziegler A, Bonifacio E . Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia. 2014; 58(2):411-3. DOI: 10.1007/s00125-014-3443-1. View

Redondo M, Steck A, Pugliese A . Genetics of type 1 diabetes. Pediatr Diabetes. 2017; 19(3):346-353. PMC: 5918237. DOI: 10.1111/pedi.12597. View

So M, Speake C, Steck A, Lundgren M, Colman P, Palmer J . Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. Endocr Rev. 2021; 42(5):584-604. DOI: 10.1210/endrev/bnab013. View

Barker J, Goehrig S, Barriga K, Hoffman M, Slover R, Eisenbarth G . Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004; 27(6):1399-404. DOI: 10.2337/diacare.27.6.1399. View

10.

Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

11.

Sims E, Geyer S, Johnson S, Libman I, Jacobsen L, Boulware D . Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care. 2019; 42(12):2228-2236. PMC: 6868467. DOI: 10.2337/dc19-0593. View

12.

Kulmala P, Savola K, Petersen J, Vahasalo P, Karjalainen J, Lopponen T . Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest. 1998; 101(2):327-36. PMC: 508571. DOI: 10.1172/JCI119879. View

13.

Mathieu C, Lahesmaa R, Bonifacio E, Achenbach P, Tree T . Immunological biomarkers for the development and progression of type 1 diabetes. Diabetologia. 2018; 61(11):2252-2258. DOI: 10.1007/s00125-018-4726-8. View

14.

Ziegler A, Rewers M, Simell O, Simell T, Lempainen J, Steck A . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309(23):2473-9. PMC: 4878912. DOI: 10.1001/jama.2013.6285. View

15.

Eisenbarth G . Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986; 314(21):1360-8. DOI: 10.1056/NEJM198605223142106. View

16.

Steck A, Vehik K, Bonifacio E, Lernmark A, Ziegler A, Hagopian W . Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care. 2015; 38(5):808-13. PMC: 4407751. DOI: 10.2337/dc14-2426. View

17.

Liu Y, Rafkin L, Matheson D, Henderson C, Boulware D, Besser R . Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study. Diabet Med. 2017; 34(7):934-937. PMC: 5816681. DOI: 10.1111/dme.13338. View

18.

Sims E, DiMeglio L . Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes. Mol Metab. 2019; 27S:S129-S138. PMC: 6768572. DOI: 10.1016/j.molmet.2019.06.010. View

19.

Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D . Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLoS One. 2010; 5(7):e11501. PMC: 2901386. DOI: 10.1371/journal.pone.0011501. View

20.

Hippich M, Holthaus L, Assfalg R, Zapardiel-Gonzalo J, Kapfelsperger H, Heigermoser M . A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med. 2020; 2(2):149-163.e4. PMC: 7598360. DOI: 10.1016/j.medj.2020.10.003. View